Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

PHASE1CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Prevention
Interventions
DRUG

Tenofovir 1% vaginal gel

Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.

Trial Locations (5)

15213

University of Pittsburgh School of Medicine, Pittsburgh

19104

University of Pennsylvania School of Medicine, Philadelphia

23507

Eastern Virginia Medical School, Norfolk

77030

Advances in Health, Inc., Houston

Unknown

Profamilia, Santo Domingo

All Listed Sponsors
lead

CONRAD

OTHER

NCT01369303 - Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel | Biotech Hunter | Biotech Hunter